Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

ABSTRACTPulmonary arterial hypertension (PAH) is a disease with a high mortality and few treatment options to prevent the development of pulmonary vessel remodeling, pulmonary vascular resistance, and right ventricular failure. Canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is or...

Full description

Bibliographic Details
Main Authors: Luxun Tang, Qi Cai, Xiao Wang, Xiaoyu Li, Xiuchuan Li, Lianglong Chen, Yongjian Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Clinical and Experimental Hypertension
Subjects:
Canagliflozin
pulmonary arterial hypertension
sodium-glucose cotransporter 2 inhibitor
pulmonary arterial smooth muscle cell proliferation
AMP-activated protein kinase
Online Access:https://www.tandfonline.com/doi/10.1080/10641963.2023.2278205

Internet

https://www.tandfonline.com/doi/10.1080/10641963.2023.2278205

Similar Items